Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Ozempic, Wegovy and Mounjaro Spark a Weight-Loss and Diet Industry Identity Crisis
Weight-loss businesses, which long pushed calorie-counting and willpower, are grappling with the surging popularity of new drugs. Source link
Johnson & Johnson’s Talc Plan Spotlights Chapter 11 Voting Power
Johnson & Johnson’s latest plan to resolve mass cancer lawsuits through bankruptcy could force some cosmetic-talc users and their lawyers into a settlement they don’t
Exxon Mobil, Johnson & Johnson, Alphabet: Stocks That Defined the Week
Markets Stocks Here are seven major companies whose stocks moved on the week’s news Source link
Big Hospital Property Owner Expects Earnings Hit
Medical Properties Trust expects to take a roughly $300 million charge tied to a deal involving some of its holdings. Source link
FDA Forces the Only Drug for Preterm Births to Leave Market
Health Makena injections for pregnant women with previous early births are ineffective, agency says Source link
Bayer’s New American CEO to Study Wounded Pharma Giant Before Acting
Business Europe Bill Anderson aims to drive innovation and cultural change and lauds ‘compelling logic’ of Monsanto acquisition Source link
They Took This Drug to Fight Aging. But Does It Actually Work?
An antiaging crowd latched onto the diabetes drug metformin hoping it would extend lifespan. Studies give conflicting results. Source link
Farallon Capital to Wage Proxy Battle at Biotech Firm
WSJ News Exclusive Finance Farallon has nominated three directors to the board of Exelixis Source link
Hype Around Weight-Loss Drugs Shows No Signs of Abating. Neither Do the Ads.
Ads for the likes of Ozempic and Wegovy are spreading through social media feeds, subway stations and TV. Source link
Johnson & Johnson Proposes Paying $9 Billion to Settle Talc Lawsuits
A unit of the health-products company is also refiling for bankruptcy protection to seek approval for the settlement plan. Source link